TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00161486
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel 100 mg daily for 4 weeks
Study: NCT00161486
Drug: Placebo Testosterone gel
Normalized name: testosterone Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo testosterone gel daily for 4 weeks
Study: NCT02771509
Drug: ANG-3777
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/mL BB3, IV, 4 days in a row, first dose must be within 4 hours after surgery, the next three doses will be approx. 24 hours after the last dose
Study: NCT02394483
Drug: F901318 tolerability
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolerability assessments
Study: NCT02394483
Drug: F901318 pharmacokinetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetic assessments
Study: NCT01788384
Drug: Clindamycin Phosphate / Benzoyl Peroxide Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
Study: NCT01788384
Drug: Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
Study: NCT01788384
Drug: Placebo (Vehicle Gel)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
Study: NCT04680156
Drug: Previously treated with EN3835 up to 1.74 mg or Placebo in EN3835-210 or the pivotal phase 3 studies
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment to be administered - Observational only
Study: NCT00603785
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with chronic sinusitis and evidence of atopy and an elevated total IgE (\>30 and \<700 IU/ml) will be randomized to receive placebo treatment for 6 months.
Study: NCT03882788
Drug: Fentanyl (high dose)
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl (narcotic anesthesia) maintenance will be with fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr.
Study: NCT03882788
Drug: Fentanyl (low dose)
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl (narcotic anesthesia) maintenance will be with fentanyl 2 mcg/kg/hr.
Study: NCT04621565
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: No hydrocortisone or other steroids are given before, during, and after the surgery, except that patients develop postoperative adrenal insufficiency. If a patient develops postoperative adrenal insufficiency, he/she needs to receive hydrocortisone treatment (20mg at 0800 and 20mg at 1600) for one month and then check the level of morning serum cortisol to decide if it is time to start the hydrocortisone taper program.
Study: NCT04621565
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone sodium succinate is given on the operation day (100mg at 0800 \& 100mg at 2000), the postoperative day 1 (100mg at 0800 \& 50mg at 2000), and the postoperative day 2 (25mg at 0800). Hydrocortisone (po.) is then given starting from the afternoon of postoperative day 2 (20mg at 1600 and 0800) to the end of the first postoperative week, and 20mg at 0800 during the second postoperative week. This is called the hydrocortisone taper program. If a patient develops postoperative adrenal insufficiency, he/she needs to receive hydrocortisone treatment (20mg at 0800 and 20mg at 1600) for one month and then check the level of morning serum cortisol to decide if it is time to start the hydrocortisone taper program.
Study: NCT04460456
Drug: SBT6050
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses of SBT6050 in Part 1 and recommended dose in Part 2
Study: NCT03698331
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-active dosage form
Study: NCT02386306
Drug: GC021109
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01713270
Drug: drug
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin converting enzyme inhibitors, angiotensin receptor antagonist, calcium antagonists, diuretic, beta adrenoceptor blocking agents, propafenone, amiodarone
Study: NCT02116257
Drug: PCA regimen
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02250859
Drug: FMX101, Minocycline 4% foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMX101, Minocycline 4% foam to be applied twice daily for 16 consecutive days
Study: NCT00736528
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 14 days
Study: NCT03651661
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo administered as nasal spray
Study: NCT04204252
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation of NaCl in phosphate buffer solution with 0.01% TWEEN-80
Study: NCT01655680
Drug: ABT-126
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-126 Middle Dose
Study: NCT01655680
Drug: ABT-126
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-126 Low Dose
Study: NCT01655680
Drug: ABT-126
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-126 High Dose
Study: NCT01655680
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03150160
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop applied topically to the affected eye(s) in the morning and evening
Study: NCT00199069
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00199069
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02779582
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: pill with no effect
Study: NCT00199069
Drug: Dexamethasone / Prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03245489
Drug: acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 81mg/day oral
Study: NCT00171782
Drug: VALSARTAN+HYDROCHLOROTHIAZIDE
Normalized name: hydrochlorothiazide / valsartan
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01514266
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04033939
Drug: HSK3486
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04033939
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03569631
Drug: BPN14770
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg BPN14770 capsules
Study: NCT03569631
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules to mimic 25 mg BPN14770 capsules
Study: NCT01298531
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo subcutaneous (SC) injections once weekly for 8 weeks.
Study: NCT03024879
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01785420
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 90 minute intravenous infusion of saline as placebo
Study: NCT00016159
Drug: tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01034137
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: orally weekly in ascending dosages, starting at 10mg/week
Study: NCT01034137
Drug: placebo MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally weekly
Study: NCT00005583
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01451905
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo pens contain saline and are administered in the same way and volume as Victoza. The placebo pens are specially prepared for this study and will be used in the study only
Study: NCT03649633
Drug: Stress-dose Hydrocortisone plus Vitamin C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of septic shock with vitamin C and stress-dose hydrocortisone aimed at the attenuation of the systemic inflammatory response and the improvement of vasopressor responsiveness.
Study: NCT00162383
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01562158
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02213042
Drug: Aromatase Inhibitors (AIs)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects who were hormone receptor-positive were required to receive an aromatase inhibitor as combination treatment; however the choice of the aromatase inhibitor selected for each patient was determined by the patients' investigator. The AIs the Investigator could choose from were anastrozole, exemestane, and letrozole and dosing was per product information.
Study: NCT00559754
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed
Study: NCT02540226
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02540226
Drug: Topical saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03634644
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: mainly composed of corn oil
Study: NCT02215031
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00576979
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05428293
Drug: A1: Ibuprofen/Acetaminophen Fixed dose combination oral suspension (Laboratorios Silanes S.A. de C.V.)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula : 100 mg/ 125 mg /5mL Pharmaceutical Form: Oral suspension Dosage: 5mL (100 mg/125mg) Administration way: oral
Study: NCT05428293
Drug: A2: Ibuprofen (Advil®, Pfizer S.A. de C.V.)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical Form: oral suspension Formula: 2 g/100 mL Dosage: 5 mL(100 mg of Ibuprofen) Administration way: oral
Study: NCT05428293
Drug: A3: Acetaminophen (Tylenol®, from Janssen-Cilag, S.A. de C.V.)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical Form: oral suspension Formula: 3.2 g/100 mL Dosage: 3.9 mL (125 mg) Administration way: oral
Study: NCT00535366
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral inhalation from MDI
Study: NCT02557945
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be treated with 400mg pills of placebo, titrating up to 3600mg per day, or 9 tablets (3 tabs tid)
Study: NCT03712969
Drug: Shenlingcao Oral Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive Shenlingcao oral liquid combined with conventional adjuvant chemotherapy, which take 4 courses, 30 days per course, one bottle per day.
Study: NCT02269202
Drug: Crobenetine, i.v. infusion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02269202
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01100684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01649609
Drug: Mycophenolate acid
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Myfortic or CellCept - The standard of care immunosuppression treatment most commonly used for renal transplant patients
Study: NCT00447603
Drug: hydrochlorothiazide (+) losartan potassium
Normalized name: hydrochlorothiazide / losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan/hydrochlorothiazide 12.5mg tablet po qd; for a 4 week study period.
Study: NCT02148107
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00734123
Drug: Simvastatin or Atorvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 10-40 mg or Atorvastatin 20-40 mg will be prescribed according to LDL cholesterol reduction target.
Study: NCT01381900
Drug: Sulphonylurea
Normalized name: metformin and sulfonylureas
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participant's stable dose of background therapy of metformin plus sulphonylurea should be continued throughout the study.
Study: NCT04248855
Drug: KAN-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion
Study: NCT04248855
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion
Study: NCT00185068
Drug: Olmesartan medoxomil/hydrochlorothiazide
Normalized name: olmesartan medoxomil/hydrochlorothiazide 40 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02025166
Drug: lornoxicam
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain treatment with NSAID (lornoxicam) at the time of the procedure
Study: NCT00374543
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered daily for 8 weeks
Study: NCT01185821
Drug: BAF312
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAF312 was supplied in film-coated tablets in strengths of 5, 4 ,2, 1, .5 and .25 mg. The actual doses taken were 10, 2, 1.25, .5 and .25 mg taken orally once a day.
Study: NCT02605785
Drug: F-18 AV 1451
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tau PET scan
Study: NCT02835560
Drug: Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esoprazole -based quadruple therapy for 14 days: Esoprazole 20mg bid, Bismuth Potassium Citrate 220mg bid, Amoxicillin 1000mg bid, Clarithromycin 500mg bid
Study: NCT01474369
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-438 placebo-matching tablets, orally, once daily for 5 weeks.
Study: NCT00515736
Drug: Selenium (Se), Zinc (Zn), Vitamin C, Vitamin B1, Vitamin E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Se 270mcg, Zn 30mg, C 1.1g, B1 100mg, E 300mg
Study: NCT00515736
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: vehicle
Study: NCT01140373
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Three cohorts of patients each will receive escalating doses of transduced autologous chimeric T lymphocytes at 1 x 10\^7 CAR+ T cells/kg, 3 x 10\^7 CAR+ T cells/kg, and 1 x 10\^8 CAR+ T cells/kg, respectively. One patient will be initially added to the three already enrolled in cohort 1 using a new variant vector expressing the P28z CAR, and up to three patients may be added to each cohort, for a total of up to six each, in the case of Grade 3 toxicity and/or sub-optimal imaging. A 4th cohort of three patients may be added if an anti-PSMA effect is observed either immunologically or radiographically or if there is preferential targeting of the cells at a particular dose level. The dose level of the 4th cohort would be from a previously tested dose level. All patients will receive one dose of cyclophosphamide (Cy) at 300mg/m2 iv one day prior to infusion of T cells.
Study: NCT01509508
Drug: Immediate ARV treatment initiation with TDF/FTC/EFV
Approvals — FDA: no, EMA: no, PMDA: no
Description: All HIV-infected adults will be offered ART regardless of their immunological and clinical staging.~The first line regimen proposed will be Atripla (R), a fixed dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(FTC/TDF/EFV). The dosing will be 1 tablet OD.
Study: NCT02400320
Drug: Topical Spray
Normalized name: Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical spray containing Diclofenac 1.16%, Linseed Oil 3%, Menthol 5%, Methyl salicylate 10%.
Study: NCT02400320
Drug: Topical Gel
Normalized name: Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel containing Diclofenac 1.16%, Menthol 5%, Methyl salicylate 10%
Study: NCT00000328
Drug: Opioid-Related Disorders
Normalized name: DRUGS FOR ACID RELATED DISORDERS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04096391
Drug: Pain Medicine
Normalized name: Night Time Pain Medicine Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections, spinal cord stimulation, peripheral nerve stimulation, pain medication, etc.
Study: NCT03341273
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin is an azalide antibiotic and is derived from erythromycin used to treat many different types of infections caused by bacteria, such as respiratory infections.
Study: NCT01567215
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermovate creme group IV steroid. Application 2 times a day for 3 weeks or less if the granuloma disappears.
Study: NCT04052971
Drug: ABN401- Expansion Phase
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose administration: Expansion Phase The expansion phase of the study will use the dose and schedule determined to be most appropriate in the dose escalation portion of the study. This may be the MTD and/or the RP2D and will consist of cohorts of NSCLC patients with c-MET dysregulation.~Patients will receive ABN401 800 mg, administered orally once daily for 21 days until disease progression, unacceptable toxicity, or patient withdrawal.
Study: NCT04193059
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide 600 mg/m\^2 iv d1, 21 days per cycle, 4 cycles.
Study: NCT01861106
Drug: Cyclophosphamide (CTX, Cytoxan)
Normalized name: cyclophosphamide Oral Tablet [Cytoxan]
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 14.5 mg/kg IV (in the vein) infusion over 30 minutes once daily on days -6 and -5 (weight based dosing) or 50 mg/kg IV infusion over 2 hours on day -6 (weight based dosing). For post-transplant, 50/kg IV once daily x2 doses on days +3 and +4
Study: NCT00588770
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04002947
Drug: DA-EPOCH
Normalized name: Epoch Blemish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine 1.4 mg/m2 (2 mg cap) IV on Day 1, Doxorubicin 10 mg/m2/day CIVI on Days 1-4, Etoposide 50 mg/m2/day CIVI on Days 1-4, Cyclophosphamide 750 mg/m2 IV on Day 5. Prednisone 60 mg/m2 PO BID is administered daily on Days 1-5 of each cycle. Each cycle is 21 days and drugs will be given for 6 cycles.
Study: NCT01527318
Drug: Fibrate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a dosage of 400mg Bezafibrate every day during 28 weeks
Study: NCT04364048
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiation will be with platinum-based chemotherapy (cisplatin or carboplatin, with etoposide, taxane, or pemetrexed) selected at the treating physician's discretion. The chemotherapy regimen used should be administered per institutional standards following the prescribing guidelines for each drug
Study: NCT03509831
Drug: INT-2150
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Period: INT-2150~2. Period: Irsogladine maleate 2 mg+Nizatidine 150 mg
Study: NCT04400695
Drug: Capecitabine Tablets
Normalized name: Capecitabine Tablets
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered according to label, as one option for Physician's Choice (determined before randomization)
Study: NCT02517359
Drug: RV6153 matching placebo 14 day repeat dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and tolerability of repeat doses
Study: NCT02517359
Drug: RV6153 matching placebo 28 day repeat dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and tolerability of repeat doses
Study: NCT01773772
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take oral placebo suspension at 1600 h and again at 2000 h.
Study: NCT00174811
Drug: telithromycin (HMR3647)
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01736020
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01952574
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by study site staff once a month (QM) as a subcutaneous injection
Study: NCT01371630
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00665522
Drug: fentanyl iontophoretic transdermal system (40mcg) No Placebo
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mcg per dose, maximum of 6 doses/hour
Study: NCT00665522
Drug: IV PCA with standard of care opioid analgesia
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: total maximum 80 doses/24 hours
Study: NCT01371630
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01371630
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT, IV, and PO
Study: NCT03276910
Drug: EPREX
Normalized name: Eprex
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 doses at 50 IU/kg or 20 IU/kg in subcutaneous use
Study: NCT01712412
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00410410
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline, IV, 0 mg/kg, every 28 days.~Induction Period 3 months~Maintenance Period 12 months
Study: NCT02795793
Drug: Non-operative management group (NOM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: With intravenous Piperacillin with Tazobactam (Tazocin)
Study: NCT04490239
Drug: Intranasal heparin sodium (porcine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal heparin sodium